Friday, 16 October 2026European Markets

ZALARIS Stock Bullish By 27% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ZALARIS (Oslo Børs All-share Index_GI: ZAL.OL) jumped by a staggering 27.14% in 21 sessions from 28 kr to 35.60 kr at 19:40 EST on Wednesday, following the last session's upward trend. Oslo Børs All-share Index_GI is jumping 2.81% to 1,415.94 kr, following the last session's downward trend.

About ZALARIS

Zalaris ASA provides full-service outsourced personnel and payroll services. The company operates through two segments, Managed Services and Professional Services. It offers a range of payroll and human resource (HR) outsourcing services, including payroll processing, time and attendance, and travel expenses, as well as cloud-based HR functionality services, such as talent management, digital personnel archive, HR analytics, mobile solutions, etc. The company also provides consulting services; and engages in the implementation of SAP HCM, and Payroll and SuccessFactors. It serves bank, insurance, finance, health and life science, infrastructure and transportation, IT, telecom, offshore and energy, services, product, retail, and service industries, as well as public services and other institutions. Zalaris ASA has operations in Norway, Sweden, Denmark, Finland, Germany, Latvia, the United Kingdom, and internationally. The company was formerly known as Zalaris HR Services AS and changed its name to Zalaris ASA in May 2014. Zalaris ASA was founded in 2000 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ZALARIS has a trailing twelve months EPS of 2.9 kr.

PE Ratio

ZALARIS has a trailing twelve months price to earnings ratio of 12.25. Meaning, the purchaser of the share is investing 12.25 kr for every norwegian krone of annual earnings.

Volume

Today's last reported volume for ZALARIS is 20070 which is 64.62% below its average volume of 56727.

More news about ZALARIS (ZAL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com